Pluristem Therapeutics, Inc. PSTI was a big mover last session, as the company saw its shares rise more than 14% on the day. Shares moved up after the FDA granted an orphan drug designation to one of the company's treatments. This led to solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend of the company as the stock is now down 20.4% in the past one-month time frame.
None of the estimates for this med-biomed/gene industry stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Thursday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Pluristem Therapeutics carries a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.
Investors interested in the space may also consider Arena Pharmaceuticals, Inc. ARNA, sporting a Zacks Rank #1 (Strong Buy).
Is PSTI going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ARENA PHARMA (ARNA): Free Stock Analysis Report
PLURISTEM THERA (PSTI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research